Date: 2015-08-12
Type of information: Production agreement
Compound: monoclonal antibodies
Company: CMC Biologics (Denmark - USA) PATH Malaria Vaccine Initiative
Therapeutic area: Infectious diseases - Parasitic diseases
Type agreement: development manufacturing production
Action mechanism: monoclonal antibody
Disease: malaria
Details: * On August 12, 2015, CMC Biologics, a global leader in clinical and commercial development and contract manufacture of therapeutic proteins, announced it has entered into an agreement with the PATH Malaria Vaccine Initiative (MVI) for process development and manufacture of specific monoclonal antibodies to test for their capacity to protect humans from malaria infection. Under this agreement, CMC Biologics will develop a CHEF1® production cell line and process for manufacture of MVI\'s monoclonal antibody, targeting circumsporozoite protein (CSP), for use by MVI in clinical research to study protection from P. falciparum infection. Process development will be conducted at CMC Biologics\' Bothell, Washington facility and transferred to its Berkeley, California facility for GMP manufacturing. Pending successful outcome, this study may lead to evaluation of additional monoclonal antibodies, targeting different epitopes, engineered to protect humans from infection.
Financial terms:
Latest news:
